Jaffetilchin Investment Partners LLC Takes $1.71 Million Position in Athenex Inc (ATNX)

Jaffetilchin Investment Partners LLC bought a new position in Athenex Inc (NASDAQ:ATNX) in the 4th quarter, HoldingsChannel.com reports. The fund bought 107,608 shares of the company’s stock, valued at approximately $1,711,000.

Several other institutional investors have also modified their holdings of ATNX. Bank of New York Mellon Corp purchased a new stake in shares of Athenex during the second quarter worth $240,000. Laurion Capital Management LP purchased a new stake in shares of Athenex during the second quarter worth $1,600,000. Vanguard Group Inc. purchased a new stake in shares of Athenex during the second quarter worth $800,000. California Public Employees Retirement System purchased a new stake in shares of Athenex during the second quarter worth $800,000. Finally, OxFORD Asset Management LLP purchased a new stake in shares of Athenex during the second quarter worth $956,000. 2.93% of the stock is owned by institutional investors and hedge funds.

Athenex Inc (NASDAQ ATNX) traded down $0.14 during midday trading on Wednesday, reaching $15.41. The company’s stock had a trading volume of 319,800 shares, compared to its average volume of 168,783. Athenex Inc has a one year low of $11.21 and a one year high of $20.79. The company has a market capitalization of $897.77 and a price-to-earnings ratio of -5.58.

ATNX has been the subject of several recent research reports. Royal Bank of Canada initiated coverage on Athenex in a report on Thursday, September 14th. They set an “outperform” rating and a $35.00 price objective for the company. Credit Suisse Group initiated coverage on Athenex in a report on Monday, September 18th. They set an “outperform” rating and a $25.00 price objective for the company. Laidlaw initiated coverage on Athenex in a report on Tuesday, September 19th. They set a “buy” rating and a $36.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on Athenex in a report on Wednesday, October 18th. They set a “neutral” rating and a $22.20 price objective for the company. Finally, BidaskClub lowered Athenex from a “hold” rating to a “sell” rating in a report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Athenex has a consensus rating of “Buy” and an average target price of $27.64.

COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2018/01/10/jaffetilchin-investment-partners-llc-takes-1-71-million-position-in-athenex-inc-atnx.html.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Want to see what other hedge funds are holding ATNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athenex Inc (NASDAQ:ATNX).

Institutional Ownership by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit